Houlihan Lokey (HLI) is an Incredible Growth Stock: 3 Reasons Why

Zacks highlights Houlihan Lokey (HLI) as a growth buy, citing a Zacks Growth Score of A and a Zacks Rank #2 driven by strong fundamental metrics: projected EPS growth of 24.1% this year (vs. industry 19%), year‑over‑year cash flow growth of 40.3% (industry -3.5%), and a 3–5 year annualized cash flow growth of 15.9% (vs. industry 11.7%). The Zacks Consensus Estimate for the current year has risen 2.2% over the last month, supporting the bullish outlook and suggesting potential outperformance for growth-oriented investors focused on investment-banking exposure.

Analysis

Market structure: Houlihan Lokey (HLI) and other middle‑market/advisory boutiques are primary beneficiaries if M&A, restructuring and distressed advisory volumes rise; HLI’s published EPS +24% and cash‑flow +40% suggest fee capture from stressed credit and carve‑outs. Large bulge‑bracket banks lose relative share on mid‑market mandates where pricing sensitivity favors boutiques; increased advisory activity also signals higher issuance in credit and leveraged loans which will widen supply in credit markets. Cross‑asset: stronger HLI revenue correlates with wider credit spreads and higher trading volumes in distressed bonds (upside for credit funds), modest positive for equities sentiment but negative near‑term for high‑grade bond prices and USD carry if risk premia rise.

Risk assessment: Key tail risks are a sudden halt in dealflow (recession deepening), loss of key rainmakers (single‑person origination risk) and a legal/regulatory adviser‑liability hit; any of these could cut trailing fees >30% in a quarter. Immediate (days) impact is volatility around earnings and estimate revisions; short term (3–6 months) depends on credit spreads and LBO activity; long term (12–24 months) depends on macro recovery and repeatable win rates. Hidden dependencies include outsized reliance on a handful of large, non‑recurring deals and variable comp expense that can swing margin by ±500–800bps; catalysts: credit‑spread moves, Fed guidance, large announced M&A deals.

Trade implications: Direct play: tactically long HLI exposure to capture EPS momentum and boutique premium; preferred sizing 1–3% portfolio given idiosyncratic risk. Pair trade: long HLI vs short GS/MS (equal notional) for 6–12 months to isolate mid‑market outperformance; unwind if HLI underperforms M&A revenue growth by >15% QoQ. Options: implement a 6–9 month call‑spread (buy 25% OTM call, sell 50% OTM call) sized to 1% portfolio as upside lever; fund by selling a 3‑month 10% OTM put to earn premium with defined risk.

Contrarian angles: Consensus leans bullish but underestimates cyclicality — current EPS/cash metrics can be driven by a small number of large, non‑repeatable mandates so forward guidance is the better signal than headline growth. Reaction may be underdone on downside risk (i.e., HLI re‑rating if new deal pipeline stalls), as boutiques have historically seen 40–60% swings across restructuring cycles (2008/09 precedent). Unintended consequences: rising rates or a shallow recovery could increase advisory needs but compress valuations and fee pools, capping multiple expansion and limiting total return.

Key Decisions for Investors

• Establish a 1–2% long position in HLI within 2 weeks to capture near‑term EPS/cash momentum; scale to 3% only after two consecutive quarters of revenue beat or if consensus EPS rises another ≥5% over next 90 days. Place stop‑loss at 15% and target 30–40% upside over 12 months.
• Enter a 6–12 month pair trade: long HLI (1% portfolio) / short GS or MS (combined 1% portfolio) to express mid‑market boutique outperformance; exit if HLI M&A/restructuring revenue lags bulge bracket peers by >15% QoQ or if credit spreads tighten >100bp (reducing distressed advisory pipeline).
• Execute a defined‑risk options spread: buy a 6–9 month HLI call spread (buy 25% OTM, sell 50% OTM) sized to 1% portfolio equivalent, funded by selling a 3‑month 10% OTM put (net debit ≤2% portfolio); unwind if implied vol >60% or spread cost exceeds 5% of notional.
• Overweight boutique/specialty financials by +1–2% (HLI and similar advisors) and underweight bulge‑bracket IBD exposure (GS, MS) by −1–2% for a 3–9 month tactical rotation; rebalance if M&A deal counts decline >20% QoQ or if senior banker attrition at HLI exceeds two announced departures.